در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Diuretics,Aromatase inhibitors,Musculoskeletal Symptoms
- چکیده:
- چکیده انگلیسی: Background: Around 50% of women receiving Aromatase Inhibitors (AIs) develop musculoskeletal symptoms
which may become severe causing interruption of treatment. Patients with AI-induced arthralgia had higher rates of
joint effusions and fluid in the tendons, so use of diuretics may be helpful. Methods: This prospective phase II study
was conducted in department of clinical oncology and nuclear medicine, Menoufia University Hospital, Egypt, between
Jan. to Dec. 2015. Fifty Women with stage I,II and III breast cancer receiving AIs as adjuvant hormonal treatment
complaining of AIs related musculoskeletal symptoms received Lasilactone® 50 mg tablet; (an oral combination of
Frusemide 20mg/Spironolactone 50 mg), every other day for 4 weeks. Patients were assessed by modified Western
Ontario and McMaster Universities osteoarthritis (WOMAC) index for lower limb and the quick Disabilities of the
Arm, Shoulder and Hand Score (DASH) scoring system for upper limbs, Arabic versions, at baseline and after 4 weeks
of treatment. Results: The mean WOMAC pain score improved significantly (6.0 v 10; P < 0.001), the mean WOMAC
stiffness score improved (2.3 v 3.9; P = 0.002), the mean WOMAC functional score improved (8.7 v 15; P < 0.001),
the total WOMAC score improved (17 v 29; P < 0.001), also a significant difference was noticed for the quick DASH
score; total score (16 v 25; P = 0.02) After use of diuretics for 4 weeks of treatment compared with baseline scores.
Conclusions: The use of diuretics effectively reduces AI related musculoskeletal symptoms with good tolerance- انتشار مقاله: 11-02-1397
- نویسندگان: Alshimaa Mahmoud Alhanafy,Alaa Labeeb,Ashraf Khalil
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Survival,Disease volume,Metastatic prostate cancer
- چکیده:
- چکیده انگلیسی: Background and Aim: The optimal management of metastatic hormone-sensitive prostate cancer has been
controversial in recent years with introduction of upfront chemohormonal treatment based on results of several Western
studies. This changing landscape has renewed interest in the concept “disease volume”, the focus of the present study
is the Egyptian patients. Methods: Patients with hormone sensitive metastatic prostate cancer presenting at Menoufia
University Hospital, Egypt, during the period from June 2013 to May 2016, were enrolled. All received hormonal
treatment. Radiologic images were evaluated and patients were stratified according to their disease volume into high or
low, other clinical and pathological data that could affect survival also being collected and analyzed. Results: A total
of 128 patients were included, with a median age of 70 years (53.9% ≥70). About 46% had co-morbidities, 62% having
high volume disease. During the median follow up period of 28 months about half of the patients progressed and one
third received chemotherapy. On univariate analysis, disease volume, performance status (PS), prostate specific antigen
level (PSA) and presence of pain at presentation were identified as factors influencing overall survival. Multivariate
analysis revealed the independent predictor factors for survival to be PS, PSA and disease volume. The median overall
survival with 27 months was high volume versus 49 with low volume disease (hazard ratio 2.1; 95% CI 1.2 - 4.4;
P=0.02). Median progression free survival was 19 months in the high volume, as compared with 48 months in the low
volume disease patients (hazard ratio, 2.44; 95% CI, 1.42 – 7.4; P=0.009). Conclusions: Disease volume is a reliable
predictor of survival which should be incorporated with other important factors as; patient performance status and
comorbidities in treatment decision-making.- انتشار مقاله: 09-10-1396
- نویسندگان: Alshimaa Mahmoud Alhanafy,Fouad Zanaty,Reda Ibrahem,Suzan Omar
- مشاهده